Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

4.2%

1 terminated/withdrawn out of 24 trials

Success Rate

90.0%

+3.5% vs industry average

Late-Stage Pipeline

13%

3 trials in Phase 3/4

Results Transparency

0 of 9 completed trials have results

Key Signals

11 recruiting

Enrollment Performance

Analytics

Phase 1

11(45.8%)

Phase 2

5(20.8%)

Phase 3

3(12.5%)

N/A

3(12.5%)

Early Phase 1

2(8.3%)

24Total

Phase 1(11)

Phase 2(5)

Phase 3(3)

N/A(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (24)

Showing 20 of 24 trials

NCT07439133Phase 3Recruiting

Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR)

Role: lead

NCT07443696Phase 2Recruiting

PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy

Role: lead

NCT07187895Phase 2Terminated

Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis

Role: lead

NCT06398444Phase 2Active Not Recruiting

A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms

Role: lead

NCT05459844Phase 3Active Not Recruiting

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Role: lead

NCT07149831Phase 1Recruiting

A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults

Role: lead

NCT07115277Not ApplicableRecruiting

Diagnostic Efficacy and Safety of Flotufolastat F-18 Injection in Subjects With Biochemical Recurrence of Prostate Cancer

Role: lead

NCT07115238Phase 3Recruiting

Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD

Role: lead

NCT07096128Phase 1Recruiting

A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate Cancer

Role: collaborator

NCT07067905Early Phase 1Recruiting

Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma

Role: collaborator

NCT06732505Phase 1Recruiting

A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens

Role: collaborator

NCT06151808Not ApplicableCompleted

Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects

Role: lead

NCT06081686Phase 1Recruiting

Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer

Role: lead

NCT06151795Phase 1Completed

A Study to Evaluate XTR006 in Chinese Volunteers

Role: lead

NCT06211647Phase 1Recruiting

A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors

Role: collaborator

NCT06197139Phase 1Recruiting

A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors

Role: collaborator

NCT05930457Phase 1Completed

Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors

Role: collaborator

NCT05814835Phase 1Completed

First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors

Role: collaborator

NCT05885841Phase 2Completed

Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD

Role: lead

NCT05885854Phase 2Completed

XTR003 PET Radiotracer for the Detection of Viable Myocardium

Role: lead